Clinical Trial

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-05-09; most recent amendment 2026-06-16.
Status change: Not Yet Recruiting → Recruiting 2025-01-03
Trial Details
NCT Number NCT06414460
Lead Sponsor InSilico Medicine Hong Kong Limited
Conditions Locally Advanced/Metastatic Solid Tumors
Enrollment 114 participants
Start Date 2025-04-25
Primary Completion 2028-03-31 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-18